0000899243-20-025694.txt : 20200918 0000899243-20-025694.hdr.sgml : 20200918 20200918160608 ACCESSION NUMBER: 0000899243-20-025694 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200917 FILED AS OF DATE: 20200918 DATE AS OF CHANGE: 20200918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fox Jonathan C CENTRAL INDEX KEY: 0001655016 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 201184080 MAIL ADDRESS: STREET 1: C/O MYOKARDIA, INC. STREET 2: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-17 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001655016 Fox Jonathan C C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 See Remarks Common Stock 2020-09-17 4 S 0 5767 50.1576 D 377673 I See footnote Common Stock 3294 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. President and Chief Medical Officer /s/ Franco Valle, as Attorney-in-Fact 2020-09-17